Oragenics Stock (OGEN): Why The Price Increased

By Amit Chowdhry ● Dec 21, 2021
  • The stock price of Oragenics Inc (NYSEAMERICAN: OGEN) increased by 7.27% in the previous trading session. This is why it happened.

The stock price of Oragenics Inc (NYSEAMERICAN: OGEN) increased by 7.27% in the previous trading session. Investors are responding positively to Oragenics announcing it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant. 

The NRC cell expression technologies provided Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform should allow the production of cell lines within 6-8 weeks of spike gene sequence availability, compared with 6-9 months for traditional production of such cell lines. The NRC technologies, developed with support from the NRC’s Pandemic Response Challenge program, will expedite the evaluation of an Omicron-specific Terra-CoV-2 candidate in preclinical and clinical studies.

Oragenics had recently demonstrated the protection of hamsters against SARS-CoV-2 with the intranasal Terra-CoV-2 candidate, which strongly supports the further development into an IND-enabling GLP toxicology study and a first-in-human Phase 1 clinical study.

KEY QUOTE:

“Oragenics is well-positioned to develop an Omicron-specific intranasal vaccine thanks to our successful, ongoing collaboration with the NRC. We had anticipated the need for rapid development of COVID-19 vaccine candidates against new variants and can leverage the NRC cell expression platform to address Omicron and future variants.”

— Frederick W. Telling, Ph.D., Oragenics’ Executive Chairman

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.